For investors looking for chances where the market price may not completely show a company's actual worth, a methodical screening process can help find possible candidates. One method is to search for stocks that join an attractive valuation with good fundamental condition, acceptable profitability, and signs of growth. This method tries to find companies selling for less than their inherent value while steering clear of the dangers of "value traps", stocks that are inexpensive for a cause. By selecting for a good valuation grade together with acceptable marks in other important financial areas, investors can build a list of businesses that seem fundamentally healthy but possibly priced too low by the market.
ICON PLC (NASDAQ:ICLR) works as a worldwide clinical research organization, giving outsourced development services to the pharmaceutical, biotechnology, and medical device industries. Based in Dublin, the company's wide service list includes clinical research, consulting, laboratory services, and real-world evidence solutions, helping its clients manage the involved process of bringing new treatments to market. A recent fundamental review of ICON PLC indicates its stock may show an interesting situation for investors using a value-focused screening approach.
Valuation: The Center of the Chance
The most noticeable part of ICON PLC's present profile is its valuation, which gets a 7 out of 10 in ChartMill's grading system. This grade shows the stock is priced low compared to both its industry group and the wider market. This is the main filter in a "acceptable value" screen, as a low valuation is the starting point for any value investment idea. For value investors, a notable difference between market price and inherent value gives the needed "margin of safety" that Benjamin Graham supported.
Important valuation measures backing this grade include:
- Price-to-Earnings (P/E) Ratio: At 12.73, ICLR's P/E ratio is much lower than 94.74% of its Life Sciences Tools & Services industry group and below the S&P 500 average of 28.18.
- Forward P/E Ratio: Also, its Price/Forward Earnings ratio of 12.46 is more appealing than 96.49% of industry companies.
- Enterprise Value to EBITDA: This ratio, which includes debt, also positions ICLR as lower priced than 98.25% of its industry, supporting the view that the market may be setting too low a price on the company's cash-producing ability.
Financial Health and Profitability: Reviewing the Base
A low valuation by itself is not enough; a company must also be on good financial ground. ICON PLC gets an average health grade of 5 and a profitability grade of 6. These marks propose the company is not a "value trap" with a failed business model, but instead one with a steady operational foundation.
Financial Health (Grade: 5): The company shows high solvency, with a good Debt-to-Free-Cash-Flow ratio of 3.53, meaning it could pay off all its debt in under four years using its present cash flow, a result better than almost 79% of its industry. Its Debt-to-Equity ratio of 0.31 also shows a sensible balance between debt and equity financing. However, liquidity measures like the Current and Quick Ratios are not as strong as many peers, an area for investors to watch.
Profitability (Grade: 6): ICON PLC shows steady profitability, having produced positive earnings and operating cash flow in each of the last five years. Its Return on Assets (3.63%), Return on Equity (6.42%), and Return on Invested Capital (6.74%) all do better than about three-quarters of the industry. While its Gross Margin is somewhat low for the sector, its Operating Margin of nearly 14% stays healthy.
Growth: The Driver for Value Recognition
For a value investment idea to succeed, there must be a way for the market to see the company's worth. Growth, both previous and expected, gives that spark. ICON PLC's growth grade of 4 shows a varied but hopeful image. The company has a good long-term history, with Revenue increasing at an average yearly rate of 24.17% and Earnings Per Share (EPS) increasing at 15.23% over recent years. However, the last year showed drops in both Revenue and EPS. Looking ahead, analysts expect a return to slight growth, with yearly EPS growth forecast at 5.27% and Revenue growth at 2.38%. This expected stabilization, instead of continued drop, is key for value investors, as it suggests the business is not in a lasting decline.
Conclusion: A Subject for Value Review
ICON PLC shows a profile that matches a methodical value screening plan. The stock is notable for its clearly low valuation across several measures compared to its industry, the necessary beginning for a value investor. This low price is combined with average-to-acceptable grades in financial health and profitability, showing the company is fundamentally stable and produces cash. While recent growth has slowed, the long-term path and forecasts for a return to slight growth suggest the business has the possibility to develop into its valuation. For investors, the mix raises the question of whether the market is too negative on this clinical research leader, possibly making a chance where the price paid today is below the company's long-term inherent value.
A full separation of these fundamental grades can be seen in the full ChartMill Fundamental Analysis Report for ICLR.
This review of ICON PLC was found using an "Acceptable Value" screening method. Investors curious about finding other stocks that fit similar standards of good valuation joined with acceptable fundamentals can see the full screen results here.
Disclaimer: This article is for information and learning only and does not make financial advice, a suggestion, or an offer or request to buy or sell any securities. The information given is based on data supplied and should not be the only base for any investment choice. Investing includes risk, including the possible loss of original investment. You should do your own complete research and talk with a qualified financial advisor before making any investment choices.